Agios Pharmaceuticals Valuation
Is AGIO * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AGIO * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AGIO * (MX$397.93) is trading below our estimate of fair value (MX$2241.3)
Significantly Below Fair Value: AGIO * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AGIO *?
Other financial metrics that can be useful for relative valuation.
What is AGIO *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$1.68b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 35.3x |
Enterprise Value/EBITDA | -2.5x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does AGIO *'s PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 8.1x | ||
ARDX Ardelyx | 9x | 59.6% | US$1.5b |
BIOA B BioArctic | 16.6x | 48.2% | kr17.4b |
BEAM Beam Therapeutics | 1.9x | -14.4% | US$1.9b |
688062 Mabwell (Shanghai) Bioscience | 4.8x | 42.6% | CN¥12.5b |
AGIO * Agios Pharmaceuticals | 2.1x | 29.4% | Mex$1.7b |
Price-To-Book vs Peers: AGIO * is good value based on its Price-To-Book Ratio (2.1x) compared to the peer average (12.2x).
Price to Earnings Ratio vs Industry
How does AGIO *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Book vs Industry: AGIO * is good value based on its Price-To-Book Ratio (2.1x) compared to the Global Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is AGIO *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 2.1x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate AGIO *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.